To evaluate the efficacy of DS-6051b in lung cancer cell line model especially G2032R mutant ROS1 rearranged lung cancer, attempts were made to establish the in vivo model of ROS1 fusion-positive lung cancer. This evidence concerns the gene ROS1 and lung carcinoma.